翔宇医疗收盘下跌8.34%，滚动市盈率80.39倍，总市值69.79亿元

Group 1 - The core business of the company is the research, production, and sales of rehabilitation medical devices, with a wide range of products across 10 categories and over 1,000 types [2] - The company has received multiple awards for its projects, including first prizes from the Chinese Rehabilitation Medicine Association and various provincial awards for technological advancements in rehabilitation solutions [2] - As of March 31, 2025, the company had 5,895 shareholders, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1] Group 2 - The latest quarterly report for Q1 2025 shows the company achieved a revenue of 186 million yuan, representing a year-on-year increase of 10.02%, while net profit decreased by 41.26% to 22.95 million yuan, with a gross margin of 65.30% [3] - The company's rolling price-to-earnings (PE) ratio is 80.39, significantly higher than the industry average of 51.29 and the median of 37.02, ranking it 101st in the industry [1][3] - The company operates in the medical device industry, which has an average PE ratio of 51.29 and a median of 37.02, indicating a relatively high valuation compared to its peers [1][3]